Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642707 · ClinicalTrials.gov registry record · Phase 2
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00642707 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 44 participants.
The verdict
NCT00642707, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140
Interventions
- DRUG Placebo Comparator
- DRUG PRO 140 (humanized monoclonal antibody to CCR5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642707
The ClinicalTrials.gov registry entry for NCT00642707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT00642707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642707 about?
NCT00642707 is a clinical study titled "Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection". The purpose of this study is: 1. To assess the antiviral activity of PRO 140 2. To assess the safety and tolerability of PRO 140 3. To generate additional PK, PD and safety data of PRO 140
What is the current status of trial NCT00642707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2008-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00642707?
The interventions under investigation include: Placebo Comparator (DRUG), PRO 140 (humanized monoclonal antibody to CCR5) (DRUG).
Who is sponsoring clinical trial NCT00642707?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.